Skip to main content
Premium Trial:

Request an Annual Quote

Silence Issued Japanese Patent for Screening Drugs Against Cancer-Related Pathway


Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

The patent, No. 4810095, specifically covers “the use of protein kinase N 3 for screening of therapeutic agents, thus preventing others from using PKN3 for screening purposes,” Silence said. “This new patent is broadly directed to various classes of therapeutic agents with the potential to impact the PI3-kinase pathway including short interfering RNA molecules, antibodies and small molecules, among others.”